Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Plasma cell 1NET 1Lymphoid 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Dexamethasone 315Bortezomib 165Lenalidomide 132pomalidomide 112daratumumab 95carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Injections 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ondansetron × Plasma cell × Clear all
NCT00871910 2017-10-23

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Merck Sharp & Dohme LLC

Phase 1 Completed
81 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡